Faculty of Medicine
Ain Shams University
Anesthesia and Intensive Care
and Pain Management Department

Management of Acquired Ventilator Associated Pneumonia In Critically III Patients

Essay Submitted for Partial Fulfillment for Master Degree

In Intensive Care Medicine

Presented by

Ahmed Fathy Ali Okda

{M.B.B.Ch.}

Faculty of Medicine, Menofia University

Supervised by

Prof.Dr. /Sahar Kamal Mohamed Abul Ella

Professor of Anesthesia and Intensive Care Faculty of Medicine- Ain Shams University

Dr. / Adel Mohamad Alansary

Assist. Prof. of Anesthesia and Intensive Care Faculty of Medicine- Ain Shams University

Faculty of Medicine
Ain Shams University
2013



قالوا سبحانك لا علم لنا إلا ما علمتنا إنك أنت العليم الحكيم

صدق الله العظيم

سورة البقرة - آية 32



First, I thank ALLAH the most gracious and most merciful.

I would like to express my thanks and profound gratitude to Professor *Prof. Dr. Sahar Kamal Mohamed Abul Ella*, Professor of Anesthesiology & Intensive Care, Faculty of Medicine, Ain Shams University, for her kind supervision, careful guidance, endless patience and continuous help throughout the course of this work.

I would also like to express my warm gratitude to *Dr. Adel*Mohamad Alansary, Assistant Professor of Anesthesiology

& Intensive Care, Faculty of Medicine, Ain Shams
University for his valuable advice, endless support and kind supervision

Finally, I must express my sincere appreciation for my family for support and encourage.

Ahmed Okda

LIST OF ABBREVIATIONS

AARC American Association for Respiratory Care

ARDS Acute Respiratory Distress Syndrome

ATS American Thoracic Society

AVP Arginine Vasopressin

BAL Bronchoalveolar Lavage

BMJ British Medical Journal

BPSB Blind Protected Specimen Brush

BSI Blood Stream Infection

CAMRSA Community Associated Methicillin Resistant Staphylococcus Aureus

CAP Community Acquired Pneumonia

CASS Continuous Aspiration Of The Subglottic Secretions

CF Complement fixation

CFU Colony Forming Unit

CMV Cytomegalovirus

COPD Chronic Obstructive Pulmonary Disease

CPIS Clinical Pulmonary Infection Score

CRP C-Reactive Protein

CTSS Closed Tracheal Suctioning System

DFA Direct Fluorescence Antibody

DVT Deep Venous Thrombosis

EB Elementary Bodies

EIA Enzyme Immuno Assay

ELISA Enzyme-Linked Immunosorbent Assay

ETA Endotracheal Aspirate

ETT Endotracheal Tube

FDA Food and Drug Administration

GI Gastrointestinal

HAP Hospital Acquired Pneumonia

HCAP Health Care Associated Pneumonia

HCU High care unit

HDU High Density Unit

HIV Human Immunodeficiency Virus

HSV Herpes Simplex Virus

ICO Intracellular Organism

ICU Intensive Care Unit

IDSA Infectious Diseases Society Of America

IFA Immunofluorescent Antibody

IV Intravenous

MCCU Medical Critical Care Unit

MDR Multidrug Resistant

MIC Minimum Inhibitory Concentration

MIF Micro Immunofluorescence

MINI-BAL Mini- Bronchoalveolar Lavage

MR-PROANP Midregional Pro-Atrial Natriuretic Peptide

ND No Data

NHSN National Healthcare Safety Network

PBP Penicillin Binding Protein

PCR Polymerase chain reaction

PCT Procalcitonin

PEEP Positive End Expiratory Pressure

PPMS Potentially Pathogenic Microorganisms

PSB Protected Specimen Brush

PTA Polymyxin e, Tobramycin, and Amphotericin b

RB Reticulate Bodies

RCTS Randomized Controlled Trials

RIA Radio immunoassay

SDD Selective Digestive Decontamination

SCCU Surgical Critical Care Unit

SEC Squamous Epithelial Cells

SSSI Skin And Skin-Structure Infection

STREM-1 Soluble Triggering Receptor Expressed On Myeloid Cells-1

TREM- 1 Triggering Receptor Expressed On Myeloid Cells-1

UTI Urinary Tract Infection

VAP Ventilator Associated Pneumonia

VRE Vancomycin Resistant Enterococci

CONTENTS

	Page
Introduction	1
Aim of the work	3
Pathophysiology and risk factors of acquired ventilator	5
associated pneumonia in critically ill patients.	
Diagnosis of acquired ventilator associated pneumonia in	20
critically ill patients.	
Treatment of acquired ventilator associated pneumonia in	54
critically ill patients.	
Prevention of acquired ventilator associated pneumonia in	75
critically ill patients.	
Summary.	98
References.	104
Arabic summary.	

LIST OF TABLES

No.	Title	Page
Table 1	Host defenses (pulmonary)	8
Table 2	Organisms associated with VAP	12
Table 3	Comparison of techniques between ETA, BAL and PSB	30
Table 4	Ranges of sensitivity and specificity for ETA, BAL and PSB	30
Table 5	Criteria for the assessment of a good quality respiratory sample in ventilator associated pneumonia and recommended threshold to distinguish between colonization and infection for quantitative culture	31
Table 6	Modified clinical pulmonary infection score	36
Table 7	Diagnosis of fungal infection	41
Table 8	Potential pathogens and recommended initial antimicrobial treatment for early-onset ventilator associated pneumonia with no risk factors for multidrug-resistant pathogens	56
Table 9	Potential pathogens and recommended initial antimicrobial treatment for ventilator associated pneumonia when late-onset or other risk factors for multidrug-resistant Pathogens are present	57

LIST OF FIGURES

No.	Title	Page
Fig. (1)	Major areas of oropharyngeal colonization	13
Fig.(2)	Chest X-ray of a patient with VAP	22
Fig.(3)	High incidence of inadequate antimicrobial therapy in nosocomial infections (ventilator associated pneumonia and bacteremia) and its association with increased mortality.	58
Fig.(4)	Inadequate antimicrobial therapy in ventilator associated pneumonia and its association with increased resource utilization	59
Fig.(5)	Follow-up for patients having ventilator associated pneumonia according to microbiological results and clinical assessment.	65
Fig.(6)	Continuous aspiration of the subglottic secretions (CASS).	83

INTRODUCTION

Pneumonia is the second most common nosocomial infection and is a leading cause of death due to hospital-acquired infection (**Tablan OC et al., 2003**).

Ventilator-associated pneumonia (VAP) is a form of nosocomial pneumonia that occurs in patients receiving mechanical ventilation for longer than 48 hour (**Pickett KE, 2008**).

The incidence of VAP differs Between different types of ICU units, hospitals (public and private sector) and countries (developed and developing) the range varies from 9% to 27% (**Klompas M, 2007**).

VAP is associated with increases in morbidity, mortality, hospital length of stay and costs. Although any patient with an endotracheal tube in place for more than 48 hours is at risk for VAP, certain patients are at higher risk like patient with preexisting conditions such as immunosuppression and chronic obstructive lung disease. The Mortality rates in patients with VAP range from 20% to 50% and may be as high as 70% when the infection is caused by multidrug resistant pathogens (**ReaNeto A et al., 2008**).

Pathophysiology of VAP involves 2 main processes: colonization of the respiratory and digestive tracts and microaspiration of secretions of the upper and lower parts of the airway (**Kunis Ka et al., 2003**).

Because every patient who is intubated and receiving ventilatory support is at risk for VAP. Making an accurate diagnosis of this disease and starting treatment is critical. The diagnosis can be made on the basis of radiographic findings, clinical findings and results of microbiological tests of sputum or invasive testing such as bronchoscop (**Porzecanski I et al., 2006**).

Treatment should be started when there is a clinical suspicion of VAP choice of antimicrobial based on patient factors and local resistance pattern (Pieracci FM et al., 2007).

VAP is preventable and certain practices have been demonstrated to reduce its incidence and its associated burden of illness (Muscedere J et al., 2008).

Prevention of VAP is possible through the use of strategies intended to minimize endotracheal intubation, The duration of mechanical ventilation and the risk of aspiration of oropharyngeal pathogens (**Pieracci FM et al., 2007**).

Aim of The Work

This essay discusses the up to date measures which could be used for diagnosis, treatment, prevention and control of acquired ventilator associated pneumonia in critically ill patients.

Pathophysiology & Risk Factors of Acquired Ventilator Associated Pneumonia in Critically Ill Patients



PATHOPHYSIOLOGY AND RISK FACTORS

The term "nosocomial infection" generally used includes all microbial diseases that develop in hospitalized patient after the expiry of the supposed incubation period of the disease. Recent advances in medical and surgical techniques have improved the outlook for many patients suffering from severe or potentially fatal diseases. However, the procedures used to cure or alleviate the illness carry frequently a very high risk of infection (**Chastre J et al., 2002**).

Nosocomial pneumonia is the leading cause of death from nosocomial infections. Aspiration of bacteria directly from the oropharynx or around the artificial airway are important factors in the pathogenesis of nosocomial pneumonia. Most cases of nosocomial pneumonia occur in patients without respiratory devices. However, patients receiving mechanical ventilation through an endotracheal tube have a fourfold increase in risk for hospital acquired pneumonia (**Fridkin SK, 2001**).

Infection occurs when the patient aspirates minute quantities of upper respiratory secretions because of the decreased cough and sneezing reflexes, impaired mucociliary transport or intubation that allows secretions to enter the lung around the tube. These infections begin with colonization of the upper respiratory tract by pathogenic microorganisms that are then aspirated into the lung (Rello J et al., 2008).

Infections of the lower respiratory tract form most common of the recorded hospital acquired infections. Colonization of the lower respiratory tract by gram negative aerobic bacilli is particularly common in patients undergoing mechanical ventilation whether by tracheostomy or by endotracheal tube (Hayon J et al., 2002).

Some hospital acquired infections are not different from infections with the same microorganisms in the general population, but many are profoundly influenced by the patients underlying illness or by medical or surgical treatment undergone in hospitals. The source of the infecting organisms may be "exogenous" from another patient or a member of the hospital staff, or from inanimate environment in the hospital, or it may be "endogenous" from the patients own flora (Fagon JY et al., 2000).

Susceptibility to infection is also related to the patient's length of stay in the critical care unit, surgical critical care unit (SCCU) patients were more susceptible to nosocomial infection than medical critical care unit (MCCU) patients (31% vs24 %) and the rate of nosocomial infections was nearly twice in SCCU patients compared to MCCU patients (62% vs 35%) (Fagon JY et al., 2000).

Pneumonia is defined as inflammation of the lung parenchyma caused by infection. Ventilator-associated pneumonia (VAP) is defined as pneumonia occurring >48 - 72 hours after endotracheal intubation VAP is therefore also a nosocomial infection, i.e. an infection that develops >48 hours after a patient has been admitted to a hospital or health care facility (**Pickett KE, 2008**).

The classification scheme for pneumonia as outlined by the American Thoracic Society Guidelines for the Management of Adults with Pneumonia refers to nosocomial pneumonia as hospital acquired pneumonia (HAP), which includes both VAP and health care-associated pneumonia (HCAP) Both are clinically and microbiologically distinct from community-acquired pneumonia (CAP) (Pieracci FM et al., 2007).

Ventilator-associated pneumonia remains the most common and fatal nosocomial intensive care unit infection among mechanically ventilated patients (Rello J et al., 2008).